| A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder (NCT07747389) | Intra-Cellular Therapies, Inc. | 2026-10-20 |
| A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects (NCT06786286) | Intra-Cellular Therapies, Inc. | 2025-01-28 |
| Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients (NCT06690398) | Intra-Cellular Therapies, Inc. | 2024-11-22 |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder (NCT06701903) | Intra-Cellular Therapies, Inc. | 2024-11-21 |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia (NCT06651567) | Intra-Cellular Therapies, Inc. | 2024-10-22 |
| Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder (NCT06627413) | Intra-Cellular Therapies, Inc. | 2024-08-23 |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease (NCT06540833) | Intra-Cellular Therapies, Inc. | 2024-08-15 |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder (NCT06480383) | Intra-Cellular Therapies, Inc. | 2024-08-05 |
| Study of Lumateperone in the Treatment of Patients With Bipolar Mania (NCT06462612) | Intra-Cellular Therapies, Inc. | 2024-07-17 |
| Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania (NCT06462586) | Intra-Cellular Therapies, Inc. | 2024-06-19 |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients (NCT06372964) | Intra-Cellular Therapies, Inc. | 2024-05-14 |
| Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder (NCT06557902) | Intra-Cellular Therapies, Inc. | 2024-05-10 |
| PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (NCT06299410) | Intra-Cellular Therapies, Inc. | 2024-04-11 |
| Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder (NCT06229210) | Intra-Cellular Therapies, Inc. | 2024-01-25 |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (NCT05850689) | Intra-Cellular Therapies, Inc. | 2023-05-02 |
| Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease (NCT05766813) | Intra-Cellular Therapies, Inc. | 2023-03-13 |
| Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers (NCT05732194) | Intra-Cellular Therapies, Inc. | 2023-01-18 |
| A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects (NCT05470101) | Intra-Cellular Therapies, Inc. | 2022-07-26 |
| An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (NCT05061719) | Intra-Cellular Therapies, Inc. | 2021-10-08 |
| Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (NCT05061706) | Intra-Cellular Therapies, Inc. | 2021-09-30 |
| Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (NCT04985942) | Intra-Cellular Therapies, Inc. | 2021-07-30 |
| Lumateperone for the Prevention of Relapse in Patients With Schizophrenia (NCT04959032) | Intra-Cellular Therapies, Inc. | 2021-07-08 |
| Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder (NCT04779177) | Intra-Cellular Therapies, Inc. | 2021-03-12 |
| Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia (NCT04709224) | Intra-Cellular Therapies, Inc. | 2020-12-30 |
| Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers (NCT04934124) | Intra-Cellular Therapies, Inc. | 2020-12-23 |
| Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder (NCT04285515) | Intra-Cellular Therapies, Inc. | 2020-02-27 |
| Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure (NCT03387215) | Intra-Cellular Therapies, Inc. | 2018-07-10 |
| Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement (NCT03489772) | Intra-Cellular Therapies, Inc. | 2018-07-10 |
| Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally (NCT03249376) | Intra-Cellular Therapies, Inc. | 2017-11-27 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease (NCT03257046) | Intra-Cellular Therapies, Inc. | 2017-09-28 |